Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

Chiba,Itaru; Ogawa,Kazuhiko; Morioka,Takamitsu; Shimoji,Hideaki; Sunagawa,Nao; Iraha,Shiro; Nishimaki,Tadashi; Yoshimi,Naomi; Murayama,Sadayuki

doi:10.3892/ol.2010.199

Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

Authors:
- Itaru Chiba
- Kazuhiko Ogawa
- Takamitsu Morioka
- Hideaki Shimoji
- Nao Sunagawa
- Shiro Iraha
- Tadashi Nishimaki
- Naomi Yoshimi
- Sadayuki Murayama
View Affiliations

Affiliations: Department of Radiology, University of the Ryukyus School of Medicine, Okinawa 903-0215, Japan, Department of Pathology, University of the Ryukyus School of Medicine, Okinawa 903-0215, Japan, Department of Surgery, University of the Ryukyus School of Medicine, Okinawa 903-0215, Japan
Published online on: October 27, 2010 https://doi.org/10.3892/ol.2010.199
Pages: 21-28

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to investigate whether glucose transporter-1 (GLUT-1) expression in a pretreatment esophageal cancer biopsy was predictive of clinical outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). A total of 25 patients with esophageal cancer treated with concurrent CRT were reviewed. Radiotherapy was administered up to total doses of 40-66.6 Gy (median 66.6 Gy) with a single fraction of 1.8-2 Gy. Regarding chemotherapy, cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 2-6) were used concurrently with radiotherapy, every 3-4 weeks for a total of 1-2 courses. Tissue samples from esophageal carcinoma were obtained from the 25 patients by biopsy prior to concurrent CRT, and a semiquantitative analysis of GLUT-1 expression was performed using immunohistochemical staining. High GLUT-1 expression was observed in 7 of 25 (28%) patients, and GLUT-1 expression was significantly correlated with clinical T stage (p=0.0454), clinical N stage (p=0.0324) and initial response to CRT (p=0.0185). Patients with a high GLUT-1 expression had significantly poorer local control (LC) (5-year LC 28.6%) than those with a low expression (5-year LC 73.4%, p<005). Multivariate analysis revealed that GLUT-1 and the number of chemotherapy courses were independent prognostic factors for LC. Patients with a high GLUT-1 expression had significantly lower recurrence-free survival (RFS) compared to those with a low GLUT-1 expression (p=0.0405). Multivariate analysis revealed that GLUT-1, the number of chemotherapy courses and clinical M stage were independent prognostic factors for RFS. GLUT-1 expression was significantly correlated with clinical T stage, clinical N stage and initial response to concurrent CRT, and was predictive of LC and RFS for patients with esophageal cancer treated with concurrent CRT.

View Figures

View References

1	Roth JA, Putnum JB Jr, Rich TA and Forastiere AA: Cancer of the esophagus. Cancer: Principles And Practice Of Oncology. 5th edition. Devita VT Jr, Hellman S and Rosenberg SA: Lippincott-Raven; PA: pp. 980–1021. 1997
2	Earlam R and Cunha-Melo JR: Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 67:381–390. 1980. View Article : Google Scholar : PubMed/NCBI
3	Earlam R and Cunha-Melo JR: Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg. 67:457–461. 1980. View Article : Google Scholar : PubMed/NCBI
4	Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
5	Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002. View Article : Google Scholar : PubMed/NCBI
6	Behrooz A and Ismail-Beigi F: Dual control of glut1 glucose transporter gene expression by hypoxia and by inhibition of oxidative phosphorylation. J Biol Chem. 272:5555–5562. 1997. View Article : Google Scholar : PubMed/NCBI
7	Lin Z, Weinberg JM, Malhotra R, Merritt SE, Holzman LB and Brosius FC III: GLUT-1 reduces hypoxia-induced apoptosis and JNK pathway activation. Am J Physiol Endocrinol Metab. 278:958–966. 2000.PubMed/NCBI
8	Pessin JE and Bell GI: Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol. 54:911–930. 1992. View Article : Google Scholar : PubMed/NCBI
9	Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I and West C: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 7:928–934. 2001.PubMed/NCBI
10	Airley RE, Loncaster J, Raleigh JA, et al: GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer. 104:85–91. 2003. View Article : Google Scholar : PubMed/NCBI
11	Brown RS and Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. Cancer. 72:2979–2985. 1993. View Article : Google Scholar : PubMed/NCBI
12	Haber RS, Weiser RL, Pritsker A, Reder I and Burstein DE: Glut-1 glucose transporter in benign and malignant thyroid nodules. Thyroid. 7:363–367. 1997. View Article : Google Scholar : PubMed/NCBI
13	Mellanen P, Minn H, Grenman R and Harkonen P: Expression of glucose transporters in head and neck tumors. Int J Cancer. 56:622–629. 1994. View Article : Google Scholar : PubMed/NCBI
14	Chang S, Lee S, Lee C, Kim JI and Kim Y: Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology. 55:448–452. 2000. View Article : Google Scholar : PubMed/NCBI
15	Kurata T, Oguri T, Isobe T, Ishioka S and Yamakido M: Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res. 90:1238–1243. 1999. View Article : Google Scholar : PubMed/NCBI
16	Haber RS, Rathan A, Weiser KR, et al: GLUT-1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 83:34–40. 1998. View Article : Google Scholar : PubMed/NCBI
17	Cartiana G, Fagotti G, Megathaes A, et al: Glut-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 92:1144–1150. 2001. View Article : Google Scholar : PubMed/NCBI
18	Younes M, Brown RW, Stephenson M, Gondo M and Cagle PT: Overexpression of Glut1 and Glut3 in stage 1 nonsmall cell lung carcinoma is associated with poor survival. Cancer. 80:1046–1051. 1997. View Article : Google Scholar : PubMed/NCBI
19	Tohma T, Okazumi S, Makino H, et al: Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus. 18:185–189. 2005. View Article : Google Scholar : PubMed/NCBI
20	Kato H, Takita J, Miyazaki T, et al: Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res. 22:2635–2639. 2002.PubMed/NCBI
21	Japanese Society for Esophageal Disease. Guide Lines For The Clinical And Pathologic Studies On Carcinoma Of The Esophagus. 9th edition. Kanehara Shuppan; Tokyo: pp. 59–79. 1999
22	Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:457–481. 1958. View Article : Google Scholar
23	Gehan E: A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrica. 52:203–224. 1965. View Article : Google Scholar : PubMed/NCBI
24	Cox DR: Regression models and life tables. J R Stat Soc. 34:187–220. 1972.
25	Kawamura T, Kusakabe T, Sugino T, et al: Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 92:634–641. 2001. View Article : Google Scholar : PubMed/NCBI
26	Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ and Kay EW: GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer. 125:2778–2782. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U and Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509–4515. 1996.PubMed/NCBI
28	Airley RE, Phillips RM, Evans AE, et al: Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: Results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol. 26:1477–1484. 2005.
29	Gray LH, Conger AD, Ebert M, Hornsey S and Scott OC: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:638–648. 1953. View Article : Google Scholar : PubMed/NCBI
30	Shetty M, Loeb JN, Vikstrom K and Ismail-Beigi F: Rapid activation of GLUT-1 glucose transporter following inhibition of oxidative phosphorylation in clone 9 cells. J Biol Chem. 268:17225–17232. 1993.PubMed/NCBI
31	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
32	Ogawa T, Inugami A, Hatazawa J, et al: Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-(11)C-methionine. Am J Neuroradiol. 17:345–353. 1996.PubMed/NCBI
33	Adams S, Baum R, Schumm-Drager P, Usadel K and Hor G: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med. 25:79–83. 1998. View Article : Google Scholar : PubMed/NCBI
34	Taylor MD, Smith PW, Brix WK, et al: Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg. 35:699–705. 2009. View Article : Google Scholar
35	Westerterp M, Sloof GW, Hoekstra OS, et al: 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol. 134:227–236. 2008. View Article : Google Scholar : PubMed/NCBI
36	Kato H, Takita J, Miyazaki T, et al: Correlation of 18-F- fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res. 23:3263–3272. 2003.PubMed/NCBI